2 results
Approved WMOPending
The primary hypothesis of the study is that the use of icodextrin leads to a reduction in extracellular volume compared to glucose 2.27%, but that the effects of icodextrin and glucose 2.27% on plasma will not differ.
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.